secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2026-07-30T20:30:36+00:00
Accession:  0001104659-26-088728
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm appoints former FDA official Peter Pitts as Executive Chairman; Frenkel and Dagher depart
--------------------------------------------------------------------------------

- Peter Pitts, former FDA Associate Commissioner, appointed Executive Chairman and Chief Strategic Regulatory Officer on July 24, 2026.
- Jacob Frenkel resigned as Chairman and director; transitions to Senior Advisor with 100,000 RSUs vesting over 6 months.
- Ibrahim Dagher resigned as EVP and Chief Medical Officer on July 26, 2026; will consult for one year with equity vesting.
- Pitts will lead NurOwn Phase 3b trial under first-ever FDA Special Protocol Assessment for an ALS therapeutic.
- Pitts receives option for 900,000 shares vesting over 4 years; no salary or cash bonus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926088728/0001104659-26-088728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926088728/tm2621592d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-088728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer